ResearcherUniversity of OxfordNo recent work listed
Mike Partridge
Matched on ORCID iD 0000-0002-8876-8190; OpenAlex author ID A5016263500. Sources: OpenAlex.
Their work
- Papers
- 7 (first author 1, last author 1)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 12
2013: 1 paper · 2014: 1 paper · 2015: 1 paper · 2016: 2 papers · 2017: 1 paper · 2018: 1 paper
Papers 7
- Stomach Dose-Volume Predicts Acute Gastrointestinal Toxicity in Chemoradiotherapy for Locally Advanced Pancreatic Cancer. Co-author DOI 10.1016/j.clon.2018.02.067↗
- Correlation of 18F-Fluorodeoxyglucose Positron Emission Tomography Parameters with Patterns of Disease Progression in Locally Advanced Pancreatic Cancer after … Co-author DOI 10.1016/j.clon.2017.01.038↗
- ARCII: A phase II trial of the HIV protease inhibitor Nelfinavir in combination with chemoradiation for locally advanced inoperable pancreatic cancer. Co-author DOI 10.1016/j.radonc.2016.03.021↗
- Conformity analysis to demonstrate reproducibility of target volumes for Margin-Intense Stereotactic Radiotherapy for borderline-resectable pancreatic cancer. Co-author DOI 10.1016/j.radonc.2016.08.001↗
- SBRT in pancreatic cancer: what is the therapeutic window? Last author DOI 10.1016/j.radonc.2014.10.015↗
- Challenges in using ¹⁸F-fluorodeoxyglucose-PET-CT to define a biological radiotherapy boost volume in locally advanced pancreatic cancer. Co-author DOI 10.1186/1748-717x-9-146↗
- Comparing dose-volume histogram and radiobiological endpoints for ranking intensity-modulated arc therapy and 3D-radiotherapy treatment plans for locally-advan… First author DOI 10.3109/0284186x.2013.813072↗
Closest collaborators
The 12 strongest of 12 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- M. Hawkins · 5 shared papers, 2014–2018 · strength 0.34
- Paper Stomach Dose-Volume Predicts Acute Gastrointestinal Toxicity in Chemoradiotherapy for Locally Advanced Pancreatic Cance… DOI 10.1016/j.clon.2018.02.067↗
- Paper Correlation of 18F-Fluorodeoxyglucose Positron Emission Tomography Parameters with Patterns of Disease Progression in L… DOI 10.1016/j.clon.2017.01.038↗
- Paper Conformity analysis to demonstrate reproducibility of target volumes for Margin-Intense Stereotactic Radiotherapy for b… DOI 10.1016/j.radonc.2016.08.001↗
- Somnath Mukherjee · 5 shared papers, 2014–2018 · strength 0.34
- Paper Stomach Dose-Volume Predicts Acute Gastrointestinal Toxicity in Chemoradiotherapy for Locally Advanced Pancreatic Cance… DOI 10.1016/j.clon.2018.02.067↗
- Paper Correlation of 18F-Fluorodeoxyglucose Positron Emission Tomography Parameters with Patterns of Disease Progression in L… DOI 10.1016/j.clon.2017.01.038↗
- Paper Conformity analysis to demonstrate reproducibility of target volumes for Margin-Intense Stereotactic Radiotherapy for b… DOI 10.1016/j.radonc.2016.08.001↗
- Thomas Baptist Brunner · 5 shared papers, 2013–2017 · strength 0.31
- Paper Correlation of 18F-Fluorodeoxyglucose Positron Emission Tomography Parameters with Patterns of Disease Progression in L… DOI 10.1016/j.clon.2017.01.038↗
- Paper SBRT in pancreatic cancer: what is the therapeutic window? DOI 10.1016/j.radonc.2014.10.015↗
- Paper Challenges in using ¹⁸F-fluorodeoxyglucose-PET-CT to define a biological radiotherapy boost volume in locally advanced … DOI 10.1186/1748-717x-9-146↗
- James Matthew Wilson · 3 shared papers, 2014–2017 · strength 0.19
- Paper Correlation of 18F-Fluorodeoxyglucose Positron Emission Tomography Parameters with Patterns of Disease Progression in L… DOI 10.1016/j.clon.2017.01.038↗
- Paper Challenges in using ¹⁸F-fluorodeoxyglucose-PET-CT to define a biological radiotherapy boost volume in locally advanced … DOI 10.1186/1748-717x-9-146↗
- Paper ARCII: A phase II trial of the HIV protease inhibitor Nelfinavir in combination with chemoradiation for locally advance… DOI 10.1016/j.radonc.2016.03.021↗
- D. Holyoake · 2 shared papers, 2016–2018 · strength 0.15
- Paper Stomach Dose-Volume Predicts Acute Gastrointestinal Toxicity in Chemoradiotherapy for Locally Advanced Pancreatic Cance… DOI 10.1016/j.clon.2018.02.067↗
- Paper Conformity analysis to demonstrate reproducibility of target volumes for Margin-Intense Stereotactic Radiotherapy for b… DOI 10.1016/j.radonc.2016.08.001↗
- Emmanouil Fokas · 2 shared papers, 2013–2016 · strength 0.09
- Paper ARCII: A phase II trial of the HIV protease inhibitor Nelfinavir in combination with chemoradiation for locally advance… DOI 10.1016/j.radonc.2016.03.021↗
- Paper Comparing dose-volume histogram and radiobiological endpoints for ranking intensity-modulated arc therapy and 3D-radiot… DOI 10.3109/0284186x.2013.813072↗
- Chris N Hurt · 1 shared paper, 2018 · strength 0.09
- Derek B. Grose · 1 shared paper, 2016 · strength 0.06
- Ganesh Radhakrishna · 1 shared paper, 2016 · strength 0.06
- Tim Maughan · 1 shared paper, 2016 · strength 0.05
- Eric E. O’Neill · 1 shared paper, 2016 · strength 0.05
- Samantha Warren · 1 shared paper, 2013 · strength 0.05
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.